Lead Product(s) : BAY1895344
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 showed promise in patients with a range of advanced, heavily pre-treated cancers, including breast, bowel, and prostate tumors in a dose-escalation portion of a first-in-human phase 1...
Product Name : BAY 1895344
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : BAY1895344
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
